ECDC Situation risk assessment    

  WHO EURO Monkeypox webpage    

Surveillance summary

A total of 4178 cases of monkeypox have been identified through IHR mechanisms and official public resources up to 28 June 2022, 14:00, from 31 countries and areas throughout the European region. Case-based data were reported for 3086 cases from 26 countries and areas to ECDC and the WHO Regional Office for Europe through The European Surveillance System (TESSy), up to 28 June 2022, 10:00.

Of the 3086 cases reported in TESSy, 3082 were laboratory confirmed. Furthermore, 87 were confirmed to be of the West African clade. The earliest date of symptom onset was reported as 17 April 2022. The majority of cases were between 31 and 40 years-old (1343/3081 - 44%) and male (3040/3055 - 99.5%). Among cases with known HIV status, 39% (275/699) were HIV-positive. The majority of cases presented with a rash (1411/1485 - 95%) and systemic symptoms such as fever, fatigue, muscle pain, vomiting, diarrhea, chills, sore throat or headache (1078/1485 - 73%). No cases were reported to have died. A few (10) cases were reported to be health workers, however further investigation is ongoing to determine whether infection was due to occupational exposure.


INTRODUCTION

PURPOSE AND SCOPE

This report provides an overview of the total number of cases of monkeypox identified by ECDC and the WHO Regional Office for Europe through IHR mechanisms and official public resources and case-based data through The European Surveillance System (TESSy) up to 28 June 2022.

The first summary table and maps (first two tabs) describe the number of cases identified through the different platforms. The following figures and tables describe national case-based data for surveillance of monkeypox reported in TESSy from all the countries and areas of the WHO European Region, including the 27 countries of the European Union (EU) and the additional three countries of the European Economic Area (EEA).

Case Report Form Data are submitted through the case-based record type MPX to The European Surveillance System (TESSy) database hosted at ECDC.

CASE DEFINITION (WHO)

As of 24 June 2022

Cases of monkeypox should be reported to TESSy if they meet any of the WHO, ECDC or national case definitions.

Confirmed case

  • Laboratory confirmed monkeypox virus by detection of unique sequences of viral DNA by real-time polymerase chain reaction (PCR)1 and/or sequencing.

Probable case:

  • A person meeting the case definition for a suspected case

AND One or more of the following:

  • has an epidemiological link [prolonged2 face-to-face exposure in close proximity, including health workers without appropriate PPE (gloves, gown, eye protection and respirator); direct physical contact with skin or skin lesions, including sexual contact; or contact with contaminated materials such as clothing, bedding or utensils] to a probable or confirmed case of monkeypox in the 21 days before symptom onset;
  • has had multiple or anonymous sexual partners in the 21 days before symptom onset;
  • has detectable levels of anti-orthopoxvirus (OPXV) IgM antibody3 (during the period of 4 to 56 days after rash onset); or a four-fold rise in IgG antibody titre based on acute (up to day 5-7) and convalescent (day 21 onwards) samples; in the absence of a recent smallpox/monkeypox vaccination or other known exposure to OPXV;
  • has a positive test result for orthopoxviral infection (e.g. OPXV-specific PCR without MPXV-specific PCR or sequencing) 1.

Suspected case

  • A person of any age presenting since 01 January 2022 with an unexplained acute rash or one or more acute skin lesions

AND one or more of the following signs or symptoms:

  • headache, acute onset of fever (>38.5°C), lymphadenopathy (swollen lymph nodes), myalgia (muscle pain/body aches), back pain, asthenia (profound weakness)

AND for which the following common causes of acute rash or skin lesions do not fully explain the clinical picture:

  • varicella zoster, herpes zoster, measles, herpes simplex, bacterial skin infections, disseminated gonococcus infection, primary or secondary syphilis, chancroid, lymphogranuloma venereum, granuloma inguinale, molluscum contagiosum, allergic reaction (e.g., to plants); and any other locally relevant common causes of papular or vesicular rash.

N.B. It is not necessary to obtain negative laboratory results for listed common causes of rash illness in order to classify a case as suspected. Further, if suspicion of monkeypox infection is high due to either history and/or clinical presentation or possible exposure to a case, the identification of an alternate pathogen which causes rash illness should not preclude testing for MPXV, as coinfections have been identified.

Discarded case

  • A suspected or probable case for which laboratory testing of lesion fluid, skin specimens or crusts by PCR and/or sequencing is negative for MPXV1.
  • Conversely, a retrospectively detected probable case for which lesion testing can no longer be adequately performed (i.e., after the crusts fall off) and no other specimen is found PCR-positive, would remain classified as a probable case.

  1. PCR on a blood specimen may be unreliable and should also not be used alone as a first line diagnostic test. If blood PCR is negative and was the only test done, this is not sufficient to discard a case that otherwise meets the definition of a suspected for probable case. This applies regardless of whether the blood PCR was for OPXV or MPXV specific.

  2. Evidence is currently lacking as to the duration of exposure necessary for infection by the respiratory route, including how it relates to the severity of the index case’s disease. Characterization of this parameter is one of the goals of the case investigation form described below

  3. Serology can be used for retrospective case classification for a probable case in specific circumstances such as when diagnostic testing through PCR of skin lesion specimens has not been possible, or in the context of research with standardized data collection. The primary diagnostic test for monkeypox diagnosis is PCR of skin lesion material or other specimen such as an oral or nasopharyngeal swab as appropriate. Serology should not be used as a first line diagnostic test.

CASE DEFINITION (ECDC)

Cases of monkeypox should be reported to TESSy if they meet any of the WHO, ECDC or national case definitions.

Confirmed case :

  • A person with a laboratory-confirmed monkeypox infection (1) monkeypox virus specific PCR assay positive result or (2) orthopoxvirus-specific PCR assay positive result which is then confirmed by nucleotide sequence determination of the detected virus as MPXV) with symptom onset since 1 March 2022.

Probable case :

  1. A person with an unexplained rash1 on any part of their body AND one or more other symptom(s) of monkeypox infection2 with symptom onset since 1 March 2022

AND one of the following:

  • has a positive laboratory test result on orthopoxviral infection (e.g., orthopoxvirus-specific positive PCR without sequencing, electron microscopy, serology);
  • has an epidemiological link to a confirmed or probable case of monkeypox in the 21 days before symptom onset;
  • reports travel to MPX endemic countries in the 21 days before symptom onset;
  • is a person (of any sexual orientation) who had multiple or anonymous sexual partners in the 21 days before symptom onset;
  • is a man who has sex with men.

OR

  1. A person with an unexplained generalized or localized maculopapular or vesiculopustular rash with centrifugal spread, with lesions showing umbilication or scabbing, lymphadenopathy and one or more other MPX-compatible symptoms2.

  1. Since EU/EEA countries are just starting to identify cases and if testing capacity is sufficient, the above more sensitive case definition can be used. In countries with limited testing capacity for orthopoxviruses, the following description can be added to characterize the rash: ‘unexplained localized or generalized maculopapular or vesiculopustular rash potentially with umbilication or scabbing’.

  2. Fever (usually higher >38.5°C), headache, back ache, fatigue, lymphadenopathy (localized or generalized).

KEY INDICATORS

IHR SUMMARY

Summary of number of cases of monkeypox identified through IHR mechanisms and official public resources and reported to TESSy, European Region, 2022

MAP

ECDC Map

WHO-EURO Map

EPICURVES

Overall by date of notification

Overall number of cases of monkeypox, per date of notification, European Region, TESSy, 2022

Date of notification is defined as the date when the case report is notified for the first time to the place of notification, date of diagnosis is defined as the first date of clinical or laboratory diagnosis, and date of onset as the date of onset of any symptoms.

Overall by date of symptom onset

Overall number of cases of monkeypox, per date of symptom onset, European Region, TESSy, 2022

Date of notification is defined as the date when the case report is notified for the first time to the place of notification, date of diagnosis is defined as the first date of clinical or laboratory diagnosis, and date of onset as the date of onset of any symptoms.

By date of onset and by country or area

Number of cases of monkeypox, per day and per country/area of notification, European Region, TESSy, 2022

Date of notification is defined as the date when the case report is notified for the first time to the place of notification, date of diagnosis is defined as the first date of clinical or laboratory diagnosis, and date of onset as the date of onset of any symptoms.

By date of onset and by country or area - country/area level

Number of cases of monkeypox, per day and per country/area of notification, European Region, TESSy, 2022

*Day of symptom onset or earliest of day of diagnosis or notification if missing

SUMMARY TABLE

Summary of number of probable and confirmed cases of monkeypox by reporting country/area, European Region, TESSy, 2022

DEMOGRAPHICS

Age and sex distribution of cases of monkeypox, European Region, TESSy, 2022

Information on sex is missing for 31 cases and information on age is missing for 5 cases.

CLINICAL DESCRIPTION

Distribution of symptoms among those reporting at least one type of symptom (N=1485), European Region, TESSy, 2022

The average time between symptom onset and diagnosis was 7 days.

Distribution of rash and systemic symptoms among those reporting at least one type of symptom (N=1485), European Region, TESSy, 2022

*Fever, fatigue, muscle pain, vomiting, diarrhea, chills, sore throat, headache

Detection of asymptomatic cases is dependent on testing guidelines which currently do not recommend testing of asymptomatic persons

OUTCOME, HIV STATUS, HCW

Summary of outcome, HIV status of cases, and cases of monkeypox among health workers, European Region, TESSy, 2022

*Includes cases hospitalized for isolation or treatment (15 cases were hospitalized for isolation purposes,29 required clinical care and 32 were hospitalized for unknown reasons).

SEXUAL ORIENTATION

Summary of reported sexual orientations among cases of monkeypox, European Region, TESSy, 2022

Sexual orientation in TESSy is defined according to the following non-mutually exclusive categories:

  • Heterosexual
  • MSM = MSM/homo or bisexual male
  • Women who have sex with women
  • Bisexual
  • Other
  • Unknown or undetermined

Sexual orientation is not necessarily representative of the gender of the person the case had sex with in the past 21 days nor does it imply sexual contact and sexual transmission.

We summarize here the sexual orientation that male cases identified with. No differences were observed across age groups.

MICROBIOLOGICAL ANALYSES

SPECIMEN TYPES

Summary of specimen types with positive test result used for diagnosis of monkeypox, European Region, TESSy, 2022

PHYLOGENETICS

Phylogenetics of monkeypox virus

Available whole genome sequences of MPXV were extracted from GISAID EpiPox and GenBank. The phylogenetic analysis was performed using ParSNP with MT903344.1 as reference and visualized using Microreact.
Figure A shows the two genetically distinct major clades described for MPXV, the Central African (Congo Basin) and West African clades.

The 2022 MPXV sequences from Europe are part of a distinct cluster within the West African clade (Figure B) and cluster together with 2022 MPXV sequences from Brazil, Canada and the US. Sequences from 2022 are indicated with coloured circles. Two 2022 sequences from the US do not cluster with the other 2022 outbreak sequences. Available information indicate that these are sporadic cases not linked to the current outbreak.

Limited sampling and sequencing of MPXV over the past years make it difficult to generate a hypothesis on the source of introduction for this outbreak at the moment.

Figure A. Phylogenetic tree of monkeypox virus sequences as of 27 June 2022.

Figure B. Phylogenetic tree of monkeypox virus sequences from West African clade as of 27 June 2022.

Disclaimers and Acknowledgments

Acknowledgments

We gratefully acknowledge the input of national public health staff involved in surveillance activities and data submission to TESSy.